Yaeger, Rona

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 139

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 94

BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape

Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 92

A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

Singhal, A., Styers, H. C., Rub, J., Li, Z., Torborg, S. R., Kim, J. Y., Grbovic-Huezo, O., Feng, H., Tarcan, Z. C., Sahin Ozkan, H., et al. (2024) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 84

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 82

Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma

Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 74

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

Weiss, J., Yaeger, R. D., Johnson, M. L., Spira, A., Klempner, S. J., Barve, M. A., Christensen, J. G., Chi, A., Der-Torossian, H., Velastegui, K., et al. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 73

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

Strickler, J. H., Satake, H., Hollebecque, A., Sunakawa, Y., Tomasini, P., Bajor, D. L., Schuler, M. H., Yaeger, R., George, T. J., Garrido-Laguna, I., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 45

Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting

Yaeger, R., & Solit, D. B. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 39

Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches

Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 35

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Tabernero, J., Bendell, J., Corcoran, R., Kopetz, S., Lee, J., Davis, M., Christensen, J., Chi, A., Kheoh, T., & Yaeger, R. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 28

434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)

Fakih, M., Falchook, G. S., Hong, D. S., Yaeger, R. D., Chan, E., Mather, O., Cardona, P., Dai, T., & Strickler, J. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 25

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell

Colorectal Cancer Treatments and StudiesCancer Cells and Metastasis

Cited by 23

BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy

Yaeger, R., & Saltz, L. (2012) · Journal of the National Comprehensive Cancer Network

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18

Abstract 2308: Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)

Hong, D. S., Kuboki, Y., Yaeger, R., Strickler, J. H., Masuishi, T., Langer, C., Shergill, A., Kim, E., Hindoyan, A., Tran, Q., et al. (2023) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 8

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

Van Cutsem, E., Yaeger, R., Delord, J.-P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., et al. (2023) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023)

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 0